Biogen Idec Inc (BIIB) 339.97 $BIIB
Majority Of IBD 50 Firms Strong On Sponsorship
at Investor's Business Daily - Fri Aug 22, 5:37PM CDT
Earnings growth fuels a stock's price performance, but that's not the only ingredient for a stock's success. Rising mutual fund sponsorship also helps. Stocks with solid sponsorship aren't hard to find every week in the IBD 50, but sponsorship runs...
Data on Celgene's Revlimid Published in Oncology Journal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 4:35PM CDT
Encouraging data was published on Celgen's (CELG) Revlimid in DLBCL.
Biogen Idec appoints Adriana (Andi) Karaboutis as EVP of its Technology and Business Solutions
M2 - Fri Aug 22, 5:25AM CDT
Medicine company Biogen Idec (NasdaqGS:BIIB) disclosed on Thursday the election of Adriana (Andi) Karaboutis as executive vice president of its Technology and Business Solutions.
Watch for Biogen Idec to Potentially Rebound After Falling 1.15% Yesterday
Comtex SmarTrend(R) - Thu Aug 21, 3:53PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $337.19 to a high of $344.42. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $340.67 on volume of 663,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Biogen Idec Names Adriana Karaboutis EVP, Technology and Business Solutions
Business Wire - Thu Aug 21, 6:00AM CDT
Biogen Idec (NASDAQ: BIIB) today announced the appointment of Adriana (Andi) Karaboutis as executive vice president, Technology and Business Solutions, effective September 24, 2014. She will report directly to the company's chief executive officer, George Scangos, Ph.D., and will be a member of the Biogen Idec management team.
What Investors Gain from Large, Mid & Small-Cap Growth Funds - Mutual Fund Commentary
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 2:02PM CDT
For investors looking to invest in growth funds, we will suggest here the top growth funds from each market capitalization. These funds carry a Zacks Mutual Fund Rank #1 (Strong Buy) as we expect the funds to outperform its peers in the future
Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 20, 10:08AM CDT
Last week, hepatitis C virus treatments remained in focus with Achillion and Gilead providing updates on ACH-3102 and Sovaldi, respectively.
US Orphan Drug Clinical Pipeline Insight 2014 - New Report on the $49 Billion Industry
M2 - Wed Aug 20, 8:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q26z36/us_orphan_drug) has announced the addition of the "US Orphan Drug Clinical Pipeline Insight 2014" report to their offering. In 2013, the US market for orphan drugs was estimated worth US$ 49 Billion. With factors like government support, high profitability and many more, this market is expected to surpass US$ 60 Billion by 2018. The orphan drugs enjoy significant competitive advantages owing to the market exclusivity period after the drug has been authorized. Through this clause, the manufacturer of orphan drugs is given a monopoly status in the market because according to the law, no other company is allowed to market the orphan drugs during the exclusivity period. Additionally, this monopolistic power is further strengthened with the fact that no other alternative health technology exists for many orphan drugs. In US, the research & development of orphan drugs is facilitated by public programs, government regulations, and policies. The major incentives for research & development of orphan drug include grants, research support, fee waivers, tax incentives, and orphan drug market exclusivity. In a highly specialized market like that of orphan drugs, though the impact of market exclusivity in the US has been positive yet relatively modest, a special platform for continued orphan drug development has been laid down by the economic incentives and public support mechanisms. US Orphan Drug Pipeline Insight 2014 - Report Highlight: - US Orphan Drug Market Insight & Orphan Drug Designation Criteria - Reimbursement Policy & FDA Regulatory Framework - US Orphan Drug Pipeline by Phase, Indication & Company - Marketed Orphan Drug Clinical Insight - US Orphan Drug Clinical Pipeline: 570 Drugs - Marketed Orphan Drugs in US: 203 Drugs - Majority Orphan Drugs in PHASE-II Development: 207 Drugs Key Topics Covered: 1. Introduction to US Orphan Market - Market Overview - Clinical Pipeline Overview 2. US Orphan Drug Regulatory Framework - Criteria for Orphan Drug Designation - Reimbursement Policy for Orphan Drugs - FDA Regulation 3. US Orphan Drug Clinical Pipeline by Phase, Indication & Company - Unknown - Research - Preclinical - Clinical - Phase-I - Phase-I/II - Phase-II - Phase-II/III - Phase-III - Preregistration - Registered 4. Marketed Orphan Drugs Clinical Insight by Indication & Company 5. Suspended & Discontinued Orphan Drugs in Clinical Pipeline by Phase, Indication & Company - No development reported - Discontinued - Market Withdrawal - Suspended 6. Competitive Landscape - Alexion - Biogen Idec - Bristol Myers Squibb - Celgene - Eli Lilly - Glaxosmithkline - Merck - Novartis Pharmaceuticals - Pfizer - Roche - Rare Disease Therapeutics - Sanofi For more information visit http://www.researchandmarkets.com/research/q2...rphan_drug
Drug Approvals, Clinical Trial Result, and Philanthropic Activity - Research Reports on Johnson & Johnson, Biogen, Amgen, Medtronic and Merck
PR Newswire - Wed Aug 20, 8:20AM CDT
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Biogen Idec Inc. (NASDAQ: BIIB), Amgen, Inc. (NASDAQ: AMGN), Medtronic, Inc. (NYSE: MDT) and Merck (NYSE: MRK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5855-100free.
Biogen Strengthens MS Portfolio with Plegridy FDA Approval - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 19, 12:20PM CDT
Plegridy's less frequent dosing schedule could help it gain share from other beta interferon treatments.
Biogen's buy rating reaffirmed
at Investor's Business Daily - Mon Aug 18, 5:40PM CDT
The biotech's overweight or buy rating was reaffirmed by Morgan Stanley on the FDA's approval of Biogen's (BIIB) new Plegridy drug for people with multiple sclerosis on Fri. The new treatment is a long-lasting form of the company's Avonex drug and...
Why Biogen Idec (BIIB) Stock Is Gaining Today
at The Street - Mon Aug 18, 10:44AM CDT
Biogen Idec (BIIB) shares are climbing on Monday after the company's relapsing multiple sclerosis drug treatment, Plegridy, was approved by the FDA.
Isis Pharmaceuticals earns USD2m for advancement of ISIS-SMN Rx in children with SMA from Biogen Idec
M2 - Mon Aug 18, 7:20AM CDT
Drug company Isis Pharmaceuticals (NasdaqGS:ISIS) reported on Friday the receipt of a USD2m milestone payment from Biogen Idec related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy (SMA).
Biogen Idec awarded US FDA approval for PLEGRIDY for treating multiple sclerosis
M2 - Mon Aug 18, 5:33AM CDT
Medicine company Biogen Idec (NasdaqGS:BIIB) reported on Friday the receipt of approval from the US Food and Drug Administration (FDA) for treating people with relapsing forms of multiple sclerosis (RMS) with the new subcutaneous injectable therapy, PLEGRIDY.
FDA approves Biogen's MS drug Plegridy
AP - Fri Aug 15, 6:27PM CDT
CAMBRIDGE, Mass. (AP) — Biogen Idec says that federal regulators have approved the specialty drugmaker's new treatment for people with relapsing forms of multiple sclerosis.
Biogen Idec's PLEGRIDY(TM)(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis
Business Wire - Fri Aug 15, 5:44PM CDT
--a^' Only Pegylated Interferon in MS, Dosed Once Every Two Weeks -
Look for Shares of Biogen Idec to Potentially Pullback after Yesterday's 1.62% Rise
Comtex SmarTrend(R) - Fri Aug 15, 3:45PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $330.70 to a high of $343.03. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $338.51 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Biogen Idec Rises 1.62% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Aug 15, 3:45PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $330.70 to a high of $343.03. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $338.51 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Majority Of IBD 50 Firms Strong On Sponsorship
at Investor's Business Daily - Fri Aug 22, 5:37PM CDT
Earnings growth fuels a stock's price performance, but that's not the only ingredient for a stock's success. Rising mutual fund sponsorship also helps. Stocks with solid sponsorship aren't hard to find every week in the IBD 50, but sponsorship runs...
Data on Celgene's Revlimid Published in Oncology Journal - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Aug 22, 4:35PM CDT
Encouraging data was published on Celgen's (CELG) Revlimid in DLBCL.
Biogen Idec appoints Adriana (Andi) Karaboutis as EVP of its Technology and Business Solutions
M2 - Fri Aug 22, 5:25AM CDT
Medicine company Biogen Idec (NasdaqGS:BIIB) disclosed on Thursday the election of Adriana (Andi) Karaboutis as executive vice president of its Technology and Business Solutions.
Watch for Biogen Idec to Potentially Rebound After Falling 1.15% Yesterday
Comtex SmarTrend(R) - Thu Aug 21, 3:53PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $337.19 to a high of $344.42. Yesterday, the shares fell 1.1%, which took the trading range below the 3-day low of $340.67 on volume of 663,000 shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Biogen Idec Names Adriana Karaboutis EVP, Technology and Business Solutions
Business Wire - Thu Aug 21, 6:00AM CDT
Biogen Idec (NASDAQ: BIIB) today announced the appointment of Adriana (Andi) Karaboutis as executive vice president, Technology and Business Solutions, effective September 24, 2014. She will report directly to the company's chief executive officer, George Scangos, Ph.D., and will be a member of the Biogen Idec management team.
What Investors Gain from Large, Mid & Small-Cap Growth Funds - Mutual Fund Commentary
Zacks Equity Research - Zacks Investment Research - Wed Aug 20, 2:02PM CDT
For investors looking to invest in growth funds, we will suggest here the top growth funds from each market capitalization. These funds carry a Zacks Mutual Fund Rank #1 (Strong Buy) as we expect the funds to outperform its peers in the future
Biotech Stock Roundup: Achillion Scores in Mid-Stage Study, Gilead's Sovaldi Remains in Focus - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Aug 20, 10:08AM CDT
Last week, hepatitis C virus treatments remained in focus with Achillion and Gilead providing updates on ACH-3102 and Sovaldi, respectively.
US Orphan Drug Clinical Pipeline Insight 2014 - New Report on the $49 Billion Industry
M2 - Wed Aug 20, 8:25AM CDT
Research and Markets (http://www.researchandmarkets.com/research/q26z36/us_orphan_drug) has announced the addition of the "US Orphan Drug Clinical Pipeline Insight 2014" report to their offering. In 2013, the US market for orphan drugs was estimated worth US$ 49 Billion. With factors like government support, high profitability and many more, this market is expected to surpass US$ 60 Billion by 2018. The orphan drugs enjoy significant competitive advantages owing to the market exclusivity period after the drug has been authorized. Through this clause, the manufacturer of orphan drugs is given a monopoly status in the market because according to the law, no other company is allowed to market the orphan drugs during the exclusivity period. Additionally, this monopolistic power is further strengthened with the fact that no other alternative health technology exists for many orphan drugs. In US, the research & development of orphan drugs is facilitated by public programs, government regulations, and policies. The major incentives for research & development of orphan drug include grants, research support, fee waivers, tax incentives, and orphan drug market exclusivity. In a highly specialized market like that of orphan drugs, though the impact of market exclusivity in the US has been positive yet relatively modest, a special platform for continued orphan drug development has been laid down by the economic incentives and public support mechanisms. US Orphan Drug Pipeline Insight 2014 - Report Highlight: - US Orphan Drug Market Insight & Orphan Drug Designation Criteria - Reimbursement Policy & FDA Regulatory Framework - US Orphan Drug Pipeline by Phase, Indication & Company - Marketed Orphan Drug Clinical Insight - US Orphan Drug Clinical Pipeline: 570 Drugs - Marketed Orphan Drugs in US: 203 Drugs - Majority Orphan Drugs in PHASE-II Development: 207 Drugs Key Topics Covered: 1. Introduction to US Orphan Market - Market Overview - Clinical Pipeline Overview 2. US Orphan Drug Regulatory Framework - Criteria for Orphan Drug Designation - Reimbursement Policy for Orphan Drugs - FDA Regulation 3. US Orphan Drug Clinical Pipeline by Phase, Indication & Company - Unknown - Research - Preclinical - Clinical - Phase-I - Phase-I/II - Phase-II - Phase-II/III - Phase-III - Preregistration - Registered 4. Marketed Orphan Drugs Clinical Insight by Indication & Company 5. Suspended & Discontinued Orphan Drugs in Clinical Pipeline by Phase, Indication & Company - No development reported - Discontinued - Market Withdrawal - Suspended 6. Competitive Landscape - Alexion - Biogen Idec - Bristol Myers Squibb - Celgene - Eli Lilly - Glaxosmithkline - Merck - Novartis Pharmaceuticals - Pfizer - Roche - Rare Disease Therapeutics - Sanofi For more information visit http://www.researchandmarkets.com/research/q2...rphan_drug
Drug Approvals, Clinical Trial Result, and Philanthropic Activity - Research Reports on Johnson & Johnson, Biogen, Amgen, Medtronic and Merck
PR Newswire - Wed Aug 20, 8:20AM CDT
Today, Analysts Review released its research reports regarding Johnson & Johnson (NYSE: JNJ), Biogen Idec Inc. (NASDAQ: BIIB), Amgen, Inc. (NASDAQ: AMGN), Medtronic, Inc. (NYSE: MDT) and Merck (NYSE: MRK). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/5855-100free.
Biogen Strengthens MS Portfolio with Plegridy FDA Approval - Analyst Blog
Arpita Dutt - Zacks Investment Research - Tue Aug 19, 12:20PM CDT
Plegridy's less frequent dosing schedule could help it gain share from other beta interferon treatments.
Biogen's buy rating reaffirmed
at Investor's Business Daily - Mon Aug 18, 5:40PM CDT
The biotech's overweight or buy rating was reaffirmed by Morgan Stanley on the FDA's approval of Biogen's (BIIB) new Plegridy drug for people with multiple sclerosis on Fri. The new treatment is a long-lasting form of the company's Avonex drug and...
Why Biogen Idec (BIIB) Stock Is Gaining Today
at The Street - Mon Aug 18, 10:44AM CDT
Biogen Idec (BIIB) shares are climbing on Monday after the company's relapsing multiple sclerosis drug treatment, Plegridy, was approved by the FDA.
Isis Pharmaceuticals earns USD2m for advancement of ISIS-SMN Rx in children with SMA from Biogen Idec
M2 - Mon Aug 18, 7:20AM CDT
Drug company Isis Pharmaceuticals (NasdaqGS:ISIS) reported on Friday the receipt of a USD2m milestone payment from Biogen Idec related to the advancement of the ongoing open-label extension study of ISIS-SMNRx in children with spinal muscular atrophy (SMA).
Biogen Idec awarded US FDA approval for PLEGRIDY for treating multiple sclerosis
M2 - Mon Aug 18, 5:33AM CDT
Medicine company Biogen Idec (NasdaqGS:BIIB) reported on Friday the receipt of approval from the US Food and Drug Administration (FDA) for treating people with relapsing forms of multiple sclerosis (RMS) with the new subcutaneous injectable therapy, PLEGRIDY.
FDA approves Biogen's MS drug Plegridy
AP - Fri Aug 15, 6:27PM CDT
CAMBRIDGE, Mass. (AP) — Biogen Idec says that federal regulators have approved the specialty drugmaker's new treatment for people with relapsing forms of multiple sclerosis.
Biogen Idec's PLEGRIDY(TM)(Peginterferon Beta-1a) Approved in the US for the Treatment of Multiple Sclerosis
Business Wire - Fri Aug 15, 5:44PM CDT
--a^' Only Pegylated Interferon in MS, Dosed Once Every Two Weeks -
Look for Shares of Biogen Idec to Potentially Pullback after Yesterday's 1.62% Rise
Comtex SmarTrend(R) - Fri Aug 15, 3:45PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $330.70 to a high of $343.03. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $338.51 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
Biogen Idec Rises 1.62% on Heavy Volume: Watch For Potential Pullback
Comtex SmarTrend(R) - Fri Aug 15, 3:45PM CDT
Biogen Idec (NASDAQ:BIIB) traded in a range yesterday that spanned from a low of $330.70 to a high of $343.03. Yesterday, the shares gained 1.6%, which took the trading range above the 3-day high of $338.51 on volume of 1.7 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
